Celsion (NASDAQ:CLSN) Issues Quarterly Earnings Results
Celsion (NASDAQ:CLSN) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.05, Fidelity Earnings reports. Celsion had a negative net margin of 1,489.20% and a negative return on equity of 53.40%. The firm had revenue of $0.13 million during the quarter, compared to analyst estimates of $0.13 million.
Celsion stock traded down $0.16 during mid-day trading on Friday, hitting $1.23. 290,200 shares of the stock were exchanged, compared to its average volume of 131,716. The company has a quick ratio of 3.47, a current ratio of 3.47 and a debt-to-equity ratio of 0.58. Celsion has a 12 month low of $1.05 and a 12 month high of $2.63. The firm’s fifty day simple moving average is $1.62 and its two-hundred day simple moving average is $1.80. The stock has a market capitalization of $25.30 million, a price-to-earnings ratio of -1.81 and a beta of 1.93.
Several research firms have issued reports on CLSN. Brookline Capital Management restated a “buy” rating on shares of Celsion in a report on Thursday, July 25th. Zacks Investment Research lowered shares of Celsion from a “hold” rating to a “sell” rating in a report on Wednesday, October 16th. Finally, ValuEngine upgraded shares of Celsion from a “sell” rating to a “hold” rating in a report on Thursday, August 1st.
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer.
Featured Story: Key terms to understand channel trading
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.